• Je něco špatně v tomto záznamu ?

Combination of Circulating Tumour DNA and 18F-FDG PET/CT for Precision Monitoring of Therapy Response in Patients With Advanced Non-small Cell Lung Cancer: A Prospective Study

O. Fiala, J. Baxa, M. Svaton, L. Benesova, R. Ptackova, T. Halkova, M. Minarik, P. Hosek, M. Buresova, J. Finek, J. Ferda, M. Pesek

. 2022 ; 19 (2) : 270-281. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22010822

BACKGROUND/AIM: Circulating tumour DNA (ctDNA) represents an emerging biomarker in non-small cell lung cancer (NSCLC). We focused on the combination of ctDNA and positron emission tomography/computed tomography (PET/CT) in the follow-up monitoring of advanced-stage NSCLC patients treated with chemotherapy. PATIENTS AND METHODS: Eighty-four patients were enrolled in this study. 18F-fluorodeoxyglucose PET/CT and ctDNA assessments were performed at baseline and after two cycles of chemotherapy (follow-up). RESULTS: There was a correlation of ctDNA with metabolic tumour volume (MTV), total lesion glycolysis (TLG), and iodine concentration (IC) at baseline (p=0.001, p=0.001, p=0.003) and at follow-up (p=0.006, p=0.002, p=0.001). The objective response was associated with follow-up ctDNA (p<0.001) and the change of all PET/CT parameters. ROC analyses showed that the combination of follow-up ctDNA with changes in SUVmax is very promising for the estimation of objective response and progression-free survival. CONCLUSION: The combination of ctDNA assessment with PET/CT is a promising approach for the follow-up monitoring of therapy response and prognosis estimation of advanced-stage NSCLC patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22010822
003      
CZ-PrNML
005      
20220506131002.0
007      
ta
008      
220425s2022 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/cgp.20319 $2 doi
035    __
$a (PubMed)35181593
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic; fialao@fnplzen.cz fiala.o@centrum.cz $u Laboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
245    10
$a Combination of Circulating Tumour DNA and 18F-FDG PET/CT for Precision Monitoring of Therapy Response in Patients With Advanced Non-small Cell Lung Cancer: A Prospective Study / $c O. Fiala, J. Baxa, M. Svaton, L. Benesova, R. Ptackova, T. Halkova, M. Minarik, P. Hosek, M. Buresova, J. Finek, J. Ferda, M. Pesek
520    9_
$a BACKGROUND/AIM: Circulating tumour DNA (ctDNA) represents an emerging biomarker in non-small cell lung cancer (NSCLC). We focused on the combination of ctDNA and positron emission tomography/computed tomography (PET/CT) in the follow-up monitoring of advanced-stage NSCLC patients treated with chemotherapy. PATIENTS AND METHODS: Eighty-four patients were enrolled in this study. 18F-fluorodeoxyglucose PET/CT and ctDNA assessments were performed at baseline and after two cycles of chemotherapy (follow-up). RESULTS: There was a correlation of ctDNA with metabolic tumour volume (MTV), total lesion glycolysis (TLG), and iodine concentration (IC) at baseline (p=0.001, p=0.001, p=0.003) and at follow-up (p=0.006, p=0.002, p=0.001). The objective response was associated with follow-up ctDNA (p<0.001) and the change of all PET/CT parameters. ROC analyses showed that the combination of follow-up ctDNA with changes in SUVmax is very promising for the estimation of objective response and progression-free survival. CONCLUSION: The combination of ctDNA assessment with PET/CT is a promising approach for the follow-up monitoring of therapy response and prognosis estimation of advanced-stage NSCLC patients.
650    12
$a nemalobuněčný karcinom plic $x diagnostické zobrazování $x farmakoterapie $x genetika $7 D002289
650    12
$a cirkulující nádorová DNA $x genetika $7 D000074141
650    _2
$a fluorodeoxyglukosa F18 $x metabolismus $x terapeutické užití $7 D019788
650    _2
$a glykolýza $7 D006019
650    _2
$a lidé $7 D006801
650    12
$a nádory plic $x diagnostické zobrazování $x farmakoterapie $x genetika $7 D008175
650    _2
$a PET/CT $x metody $7 D000072078
650    _2
$a prognóza $7 D011379
650    _2
$a prospektivní studie $7 D011446
650    _2
$a radiofarmaka $x terapeutické užití $7 D019275
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a tumor burden $7 D047368
655    _2
$a časopisecké články $7 D016428
700    1_
$a Baxa, Jan $u Department of Imaging Methods, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Svaton, Martin $u Department of Pneumology and Phtiseology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Benesova, Lucie $u Center for Applied Genomics of Solid Tumors, Genomac Research Institute, Prague, Czech Republic
700    1_
$a Ptackova, Renata $u Center for Applied Genomics of Solid Tumors, Genomac Research Institute, Prague, Czech Republic
700    1_
$a Halkova, Tereza $u Center for Applied Genomics of Solid Tumors, Genomac Research Institute, Prague, Czech Republic
700    1_
$a Minarik, Marek $u Elphogene, Prague, Czech Republic $u Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Hosek, Petr $u Laboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Buresova, Marcela $u Department of Pneumology and Phtiseology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Finek, Jindrich $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Ferda, Jiri $u Department of Imaging Methods, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Pesek, Milos $u Department of Pneumology and Phtiseology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
773    0_
$w MED00180194 $t Cancer genomics & proteomics $x 1790-6245 $g Roč. 19, č. 2 (2022), s. 270-281
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35181593 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130954 $b ABA008
999    __
$a ok $b bmc $g 1788780 $s 1162020
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 19 $c 2 $d 270-281 $e - $i 1790-6245 $m Cancer genomics & proteomics $n Cancer Genomics Proteomics $x MED00180194
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace